{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:14:42Z","timestamp":1792401282543,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0424-5","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T21:57:52Z","timestamp":1537394272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0942","authenticated-orcid":false,"given":"Stephen","family":"Salloway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A.","family":"Honigberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Friesenhahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Quartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin R.","family":"Wildsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina N.","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehnaaz","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698\u2013712.","journal-title":"Nat Rev Drug Discov"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"424_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u201398.","journal-title":"Neuron"},{"key":"424_CR4","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique A\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J Neurosci. 2012;32:9677\u201389.","journal-title":"J Neurosci"},{"key":"424_CR5","doi-asserted-by":"publisher","first-page":"39374","DOI":"10.1038\/srep39374","volume":"6","author":"M Ultsch","year":"2016","unstructured":"Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, et al. Structure of crenezumab complex with A\u03b2 shows loss of \u03b2-hairpin. Sci Rep. 2016;6:39374.","journal-title":"Sci Rep"},{"key":"424_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-\u03b2 PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560\u20136.","journal-title":"J Nucl Med"},{"key":"424_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neuroimage.2014.11.055","volume":"108","author":"M Brendel","year":"2015","unstructured":"Brendel M, H\u00f6genauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. NeuroImage. 2015;108:450\u20139.","journal-title":"NeuroImage"},{"key":"424_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567\u201374.","journal-title":"J Nucl Med"},{"key":"424_CR9","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, Cohen S, Van Dyck C, Brody M, Curtis C, Cho W, et al. ABBY: a phase 2 randomized trial of crenezumab in mild-to-moderate Alzheimer\u2019s disease. Neurology. 2018;90:e1889\u201397.","journal-title":"Neurology"},{"key":"424_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"424_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O'Bryant","year":"2008","unstructured":"O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer\u2019s research consortium study. Arch Neurol. 2008;65:1091\u20135.","journal-title":"Arch Neurol"},{"key":"424_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ana.410310303","volume":"31","author":"L Berg","year":"1992","unstructured":"Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol. 1992;31:242\u20139.","journal-title":"Ann Neurol"},{"key":"424_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/WAD.0b013e3181f883b7","volume":"25","author":"M Sano","year":"2011","unstructured":"Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, et al. Adding delayed recall to the Alzheimer disease assessment scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25:122\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"424_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12:517\u201326.","journal-title":"Alzheimers Dement"},{"key":"424_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuroimage.2010.07.033","volume":"54","author":"V Fonov","year":"2011","unstructured":"Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL, et al. Unbiased average age-appropriate atlases for pediatric studies. NeuroImage. 2011;54:313\u201327.","journal-title":"NeuroImage"},{"key":"424_CR16","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.jalz.2011.05.108","volume":"7","author":"P Coupe","year":"2011","unstructured":"Coupe P, Fonov V, Eskildsen S, Manj\u00f3n J, Arnold D, Collins L. Influence of the training library composition on a patch-based label fusion method: application to hippocampus segmentation on the ADNI dataset. Alzheimers Dement. 2011;7:S24.","journal-title":"Alzheimers Dement"},{"key":"424_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 2002;17:479\u201389.","journal-title":"NeuroImage"},{"issue":"Suppl 1","key":"424_CR18","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.neuroimage.2004.07.051","volume":"23","author":"SM Smith","year":"2004","unstructured":"Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 2004;23(Suppl 1):S208\u201319.","journal-title":"NeuroImage"},{"key":"424_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363\u201372.","journal-title":"Lancet Neurol"},{"key":"424_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"424_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198\u2013207.","journal-title":"Arch Neurol"},{"key":"424_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"424_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","volume":"12","author":"ER Siemers","year":"2016","unstructured":"Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016;12:110\u201320.","journal-title":"Alzheimers Dement"},{"key":"424_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"424_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0172-3","volume":"8","author":"S Shokouhi","year":"2016","unstructured":"Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther. 2016;8:2.","journal-title":"Alzheimers Res Ther"},{"key":"424_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jalz.2017.02.009","volume":"13","author":"AS Fleisher","year":"2017","unstructured":"Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimers Dement. 2017;13:1117\u201324.","journal-title":"Alzheimers Dement"},{"key":"424_CR27","unstructured":"Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand'Maison M, O-Neill P, et al. Impact of reference\/target region selection on amyloid PET standard uptake value ratios in the phase 1b PRIME study of aducanumab. J Nucl Med. [Epub ahead of print]."},{"key":"424_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/WNF.0b013e31823a13d3","volume":"35","author":"K Uenaka","year":"2012","unstructured":"Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2012;35:25\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"424_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fneur.2015.00186","volume":"6","author":"A Ritter","year":"2015","unstructured":"Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. Front Neurol. 2015;6:186.","journal-title":"Front Neurol"},{"key":"424_CR30","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jalz.2010.06.004","volume":"7","author":"JL Cummings","year":"2011","unstructured":"Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011;7:e13\u201344.","journal-title":"Alzheimers Dement"},{"key":"424_CR31","first-page":"LB13","volume":"2","author":"S Retout","year":"2015","unstructured":"Retout S, Gieschke R, Weber C, Charoin J, Volz D, Lasser R, et al. The importance of understanding the variable rate of progression among Alzheimer's disease patients: data from the gantenerumab program. J Prev Alzheimers Dis. 2015;2:LB13.","journal-title":"J Prev Alzheimers Dis"},{"key":"424_CR32","doi-asserted-by":"crossref","unstructured":"Klein G, Delmar P, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, et al. 24-month amyloid PET results of the gantenerumab high-dose open label extension studies. Alzheimer\u2019s Association International Conference July 22\u201326; Chicago; O1\u201309-03. 2018.","DOI":"10.1016\/j.jalz.2018.06.2380"},{"key":"424_CR33","doi-asserted-by":"crossref","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. Treatment of early AD subjects with BAN2401, an anti-A\u03b2 protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline. Alzheimer\u2019s Association International Conference July 22\u201326; Chicago; DT-01-07. 2018.","DOI":"10.1016\/j.jalz.2018.07.009"},{"key":"424_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"424_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1002\u201310.","journal-title":"Arch Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0424-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0424-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0424-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:13:57Z","timestamp":1693898037000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0424-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0424-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MW, CH, SSu, and RP were employees of Genentech Inc., South San Francisco, CA, USA at the time of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"This study was conducted at 21 sites in the US, one site in Spain, and one site in France. The study protocol was approved by the respective institutional review boards prior to participant recruitment and was conducted in accordance with US Food and Drug Administration regulations, International Council on Harmonization E6 Guideline for Good Clinical Practice, and applicable local, state, federal, and country laws. Written informed consent was obtained for all patients prior to performing study-related procedures in accordance with federal and institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LAH, WC, MW, MF, FB, AQ, DC, DM, TB, CH, CR, SPS, KRW, SSu, RNF, and RP are current or former employees of Genentech (a member of the Roche Group), and own stock or stock options in F. Hoffmann-La Roche. SSa received grants and personal fees from Genentech during the conduct of the study, grants and personal fees from Eli Lilly, Biogen Idec, Merck, and Roche, and grants from Functional Neuromodulation, Avid, and Novartis. EMR received grants from Banner Alzheimer\u2019s Institute during the conduct of the study, and is evaluating crenezumab in the Alzheimer\u2019s Prevention Initiative (API) Autosomal Dominant Alzheimer\u2019s Disease Trial. KC declares that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"96"}}